NCT01792687View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 5, 2013

Primary Completion Date

May 10, 2014

Study Completion Date

February 13, 2024

Conditions
Prostate Cancer
Interventions
DRUG

ARN-509

Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily

DRUG

Abiraterone acetate

1,000 mg, oral, daily

DRUG

Prednisone

5 mg, oral, daily

Trial Locations (1)

Unknown

Boston

Sponsors
All Listed Sponsors
lead

Aragon Pharmaceuticals, Inc.

INDUSTRY